ARTICLE
22 April 2020

Will The USPTO Extend Deadlines Under The CARES Act?

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
While a number of patent offices around the world have extended some, most, or all deadlines "in view of the disruptions to public life caused by the COVID-19 outbreak" as the EPO put it,...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

While a number of patent offices around the world have extended some, most, or all deadlines “in view of the disruptions to public life caused by the COVID-19 outbreak” as the EPO put it, the USPTO has not. Until last week, that was because the Director lacks statutory authority to extend deadlines set by statute. However, the CARES Act signed into law on Friday, March 27, 2020, grants the Director temporary authority to extend deadlines. Now we wait to see if he will do so.

Temporary Authority Under The CARES Act

Section 12004 of the ‘‘Coronavirus Aid, Relief, and Economic Security Act’’ (the “CARES Act”) is entitled “TEMPORARY AUTHORITY OF DIRECTOR OF THE USPTO DURING THE COVID–19 EMERGENCY.” The basic grant of authority to extend deadlines provides: 

(a) IN GENERAL.—During the emergency period described in subsection (e), the Director may toll, waive, adjust, or modify, any timing deadline established by title 35, United States Code, the Trademark Act, section 18 of the Leahy-Smith America Invents Act (35 U.S.C. 321 note), or regulations promulgated thereunder, in effect during such period, if the Director determines that the emergency related to such period— (1) materially affects the functioning of the Patent and Trademark Office; (2) prejudices the rights of applicants, registrants, patent owners, or others appearing before the Office; or (3) prevents applicants, registrants, patent owners, or others appearing before the Office from filing a document or fee with the Office. 

As set forth in paragraph (b), “[i]f the Director determines that tolling, waiving, adjusting, or modifying a timing deadline under subsection (a) is appropriate, the Director shall publish publicly a notice to such effect."

As set forth in paragraph (c), the “emergency period” “includes the duration of the portion of the emergency declared by the President pursuant to the National Emergencies Act on March 13, 2020, as a result of the COVID–19 outbreak (and any renewal thereof) beginning on or after the date of the enactment of this section and the 60 day period following such duration.” 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More